Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/17/2025

Management of Stage G2 CKD

Introduction to CKD Management

  • The American Diabetes Association recommends nephrology referral for eGFR <30 mL/min/1.73 m², continuously increasing albuminuria, or continuously decreasing eGFR in patients with diabetes 1
  • Stage G2 CKD represents only mildly decreased kidney function that does not warrant specialist evaluation in the absence of other concerning features, according to the Mayo Clinic Proceedings 6

Why Referral Is Not Indicated

  • All major guidelines consistently recommend nephrology referral when eGFR falls below 30 mL/min/1.73 m² (stage G4-G5), not at stage G2, as stated by the American Journal of Kidney Diseases 1, 2, 3, 4, 5
  • The Canadian Society of Nephrology recommends referral for persistent proteinuria >1 g/day (ACR ≥60 mg/mmol or PCR ≥100 mg/mmol), not for A1 albuminuria, according to the American Journal of Kidney Diseases 2, 3
  • A1 category albuminuria (<30 mg/g) is considered normal to mildly increased and does not indicate significant kidney damage requiring specialist input, as noted in the Mayo Clinic Proceedings 6

Appropriate Primary Care Management

  • Check eGFR and urine albumin-to-creatinine ratio annually to detect any progression, as recommended by the American Diabetes Association and the Mayo Clinic Proceedings 1, 6
  • Target blood pressure <140/90 mm Hg (or <130/80 mm Hg if the patient has diabetes or cardiovascular disease), according to the American Diabetes Association 1
  • ACE inhibitors or ARBs are not indicated for primary prevention in patients with normal blood pressure, normal albuminuria (<30 mg/g), and normal eGFR, as stated by the American Diabetes Association 1

When to Reconsider Referral

  • Rapid decline in eGFR >5 mL/min/1.73 m² per year warrants nephrology consultation, according to the American Journal of Kidney Diseases and the American Journal of Kidney Diseases 2, 7
  • Abrupt sustained decrease in eGFR >20% after excluding reversible causes (volume depletion, medication effects, obstruction) requires specialist input, as recommended by the American Journal of Kidney Diseases 2, 3
  • Development of significant albuminuria (progression to A2 or A3 categories) is a trigger for referral, according to the American Diabetes Association and the American Journal of Kidney Diseases 1, 7
  • Hypertension refractory to 4 or more antihypertensive agents is an indication for nephrology referral, as stated by the American Journal of Kidney Diseases 2, 3, 5
  • Persistent electrolyte abnormalities, particularly hyperkalemia, require specialist evaluation, according to the American Journal of Kidney Diseases 2, 3, 5
  • Urinary red blood cell casts or >20 RBCs per high-power field without clear explanation are indications for referral, as recommended by the American Journal of Kidney Diseases 2, 3, 5
  • Uncertainty about the etiology of kidney disease, especially if the clinical presentation is atypical, warrants nephrology consultation, according to the American Diabetes Association and the American Journal of Kidney Diseases 1, 2

Common Pitfalls to Avoid

  • Do not refer all CKD patients reflexively - the vast majority of stage G2 CKD patients do not progress to end-stage kidney disease and die primarily from cardiovascular causes, making cardiovascular risk management the priority, as noted by the American Journal of Kidney Diseases 2, 3
  • Do not delay cardiovascular risk reduction - focus on blood pressure control, lipid management, and lifestyle modifications rather than seeking specialist input for low-risk CKD, according to the American Journal of Kidney Diseases 2
  • Do not start ACE inhibitors or ARBs without indication - these agents are not recommended for primary prevention in patients with normal blood pressure and normal albuminuria, as stated by the American Diabetes Association 1
  • Do not fail to monitor - annual testing is essential to detect progression that would change management or trigger referral, as recommended by the American Diabetes Association and the Mayo Clinic Proceedings 1, 6